| Methods | D: crossover C: unclear B: double WD: 1/9 J: 1‐1‐1 DU: ‐/2x2m (no washout)/‐ | |
| Participants | N: 9/8 D: 4 migraine with, 5 without aura C: Ad Hoc F: 78% A: 23‐39 years DU: 1‐27 years S: clinical pharmacology department in Granada, Spain | |
| Interventions | P: 160 mg C: Placebo | |
| Outcomes | R: 4/8 vs. 2/8; 7 preferred propranolol, 1 no preference F: significantly fewer attacks with propranolol AU: not reported HI: not reported AEs: unclear Dropouts‐AEs: 1/9 vs. 0/9 V: + | |
| Notes | Extremely small trial with very positive results | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.